PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer

Authors

Sandeep Rajput, Washington University School of Medicine in St. Louis
Zhanfang Guo, Washington University School of Medicine in St. Louis
Shunqiang Li, Washington University School of Medicine in St. Louis
Cynthia X. Ma, Washington University School of Medicine in St. Louis

Journal

Oncotarget

Publication Date

6-4-2019

Volume

10

Issue

38

First Page

3667

Last Page

3680

Document Type

Open Access Publication

DOI

10.18632/oncotarget.26960

Rights and Permissions

Rajput S, Guo Z, Li S, Ma CX. PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer. Oncotarget. 2019 Jun 4;10(38):3667-3680. eCollection 2019 Jun 4. https://doi.org/10.18632/oncotarget.26960. Copyright: Rajput et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Rajput, Sandeep; Guo, Zhanfang; Li, Shunqiang; and Ma, Cynthia X., "PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer." Oncotarget. 10, 38. 3667 - 3680. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8993